Bladder cancer care is costly due to long surveillance periods for non-muscle-invasive bladder cancer (NMIBC) and comorbidities associated with the surgical treatment of muscle-invasive bladder cancer (MIBC).
We reviewed current evidence-based practices and propose quality metrics for NMIBC and MIBC.
For patients with NMIBC, we propose four categories of candidate quality metrics: (1) appropriate use of imaging, (2) re-staging transurethral resection of bladder tumor, (3) perioperative intravesical chemotherapy, and (4) induction and maintenance BCG in high-risk NMIBC. For patients with MIBC, we propose eight candidate quality measures: (1) neoadjuvant chemotherapy, (2) multidisciplinary consultation, (3) urinary diversion teaching, (4) appropriate perioperative antibiotics, (5) venous thromboembolic prophylaxis, (6) lymphadenectomy, (7) monitoring of complications, and (8) inclusion of enhanced recovery after surgery protocols. Marked variation in evidence-based practice exists among patients with bladder cancer and represents opportunity for quality improvement. Regional and national physician-led collaboratives may be the best vehicle to achieve quality improvement in bladder cancer.
Current urology reports. 2018 Oct 24*** epublish ***
Benjamin T Ristau, Marc C Smaldone
Urologic Oncology, Division of Urology, UConn Health, 263 Farmington Avenue, MC-8036, Farmington, CT, 06030, USA. ., Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.